Acrophyte Hospitality Trust Q1 revenue falls 7.7% to US$33.5 million
[SINGAPORE] Acrophyte Hospitality Trust 's revenue for the first quarter of 2025 fell 7.7 per cent to US$33.5 million, from US$36.2 million in Q1 2024.
In a business update on Wednesday (May 7), the managers attributed this to an 8.3 per cent year-on-year reduction in portfolio size. The stapled group now operates 33 hotels in the US.
The managers also reported 12.8 per cent lower Q1 operating profit at US$9.3 million, from US$10.7 million in the previous corresponding period.
Its net property income dropped 18.1 per cent to US$5.3 million, from US$6.4 million previously.
Lee Jin Yong, chief executive of the managers, said: 'Our operational performance during the first quarter of 2025 was affected by the absence of contributions from three disposed hotels in FY2024. Furthermore, seven hotels transitioned to new management, and utility expenses increased due to severe winter weather conditions.'
Acrophyte Hospitality Trust was previously known as ARA US Hospitality Trust.
Stapled securities of Acrophyte Hospitality Trust closed flat on Tuesday at US$0.205.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Times
20 minutes ago
- Business Times
Elon Musk taps investors for billions days after Washington exit
[NEW YORK] Elon Musk is selling US$5 billion in debt for his artificial intelligence (AI) startup, xAI, the latest in a series of fundraising efforts across his business empire as the billionaire pivots away from politics and returns to running his various companies. Morgan Stanley is shopping the debt for xAI with a double-digit interest rate, according to sources familiar with early pricing discussions. The financing could help Musk continue to spend aggressively on AI infrastructure as he builds out a massive data centre in Memphis. Musk appears eager to refocus on his array of businesses after announcing last week that he would be stepping back from politics. He had spent months as a senior adviser and regular companion to US President Donald Trump, for whom he campaigned in the 2024 election and was a top financial supporter. The debt package includes a floating-rate term loan, a fixed-rate term loan and senior secured notes, said the sources, who are not authorised to share the information publicly. The proceeds will go towards general corporate purposes, with commitments due Jun 17. Early pricing discussions are seven percentage points over the benchmark rate for the floating-rate term loan and a roughly 12 per cent yield on the senior notes, different sources with knowledge of the matter said. The debt sale has already garnered demand in excess of US$3.5 billion, they added. A representative for xAI declined to comment. Morgan Stanley did not immediately provide a comment. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up Musk's presence in Washington – where he oversaw a broad government cost-cutting initiative known as the Department of Government Efficiency – led to widespread criticism of him personally, but also concern about the performance of his companies. Shares at Tesla, where Musk is chief executive officer, are down 20 per cent since the inauguration. In addition to xAI's debt offering, Musk also raised US$650 million for his neurotechnology company, Neuralink., and is selling US$300 million in xAI stock through a secondary offering, according to the Financial Times. Investor enthusiasm Musk recently merged xAI with his social networking platform X into a combined company called XAI Holdings. He has been investing heavily in its Memphis data centre, called Colossus, which the debt sale could help finance. That operation already has 200,000 graphics processing units (GPUs) training its AI systems, and Musk aims to add one million in another location nearby, he said in a May 20 interview on CNBC. Bloomberg previously reported that the company was in talks with investors to raise roughly US$20 billion in funding, underscoring the market's enthusiasm for AI as well as Musk's standing as a business titan and political player. Morgan Stanley has a long history of working with Musk. The bank advised him on his takeover of X – then called Twitter – in 2022 and led a group of lenders that provided debt financing for the US$44 billion acquisition. They intended to immediately sell the loans to investors, but concerns about the underlying business and some of Musk's erratic decisions left banks stuck with US$13 billion of risky debt on their balance sheets for more than two years. Morgan Stanley successfully re-launched the sale process this year, getting rid of the last bits of debt in April, as Musk's standing in Washington bolstered optimism about his business prospects. The early relationship between X and xAI was also marketed as a perk for investing in the platform's bonds. Between the debt sales at or near face value, the interest payments and the advisory fees, Morgan Stanley ended up profiting handsomely from the transaction. BLOOMBERG
Straits Times
an hour ago
- Straits Times
Disney lays off hundreds in film, TV as industry woes linger
Disney has cut more than 8,000 jobs in recent years as it seeks to improve profitability. PHOTO: AFP Los Angeles - Walt Disney Co. is laying off several hundred employees across its film and TV businesses, cuts that underscore that the entertainment industry's contraction is far from over. The staff reductions began on June 2 and are falling on employees in marketing, publicity, casting and development, along with corporate financial operations, according to the company. Hollywood has been in a cost-cutting mode for several years, with production and employment in a downward spiral. Studios have reduced the number of films they release to boost profitability, particularly with cinema attendance still below pre-pandemic levels. Consumers, meanwhile, are cancelling cable-TV subscriptions in favour of streaming services, a shift that crimps advertising and distribution revenue for operators of traditional channels. The changes are prompting a massive reorganisation of the business. Comcast plans to spin off most of its cable-TV channels, including MSNBC, USA and CNBC, by the end of this year. Warner Bros. Discovery Inc. has also completed an internal restructuring to separate its studio business and its cable-TV operations, which could facilitate a divestment of the latter division. More cuts are expected at Paramount Global as it pursues a merger with independent film and TV studio Skydance Media. Disney had earlier weighed divesting its own TV networks including ABC, but ultimately decided to keep the assets. The company announced a retrenchment in February 2023, eliminating 7,000 jobs in a bid to cut expenses by US$5.5 billion (S$7.1 billion). Disney later increased that target to US$7.5 billion. Competitors have also laid off thousands of workers. The latest reductions follow roughly 200 job cuts across Disney's ABC and entertainment TV networks in March. In all, the company has eliminated more than 8,000 positions in recent years as it seeks to improve profitability. The latest layoffs were first reported by the entertainment industry publication Deadline. Disney had about 233,000 employees at the end of its last fiscal year in September, including 76 per cent full time. BLOOMBERG Join ST's Telegram channel and get the latest breaking news delivered to you.
Business Times
an hour ago
- Business Times
Merck held talks to buy biotech MoonLake for over US$3 billion: FT
MERCK has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than US$3 billion, the Financial Times reported on Monday, citing three people familiar with the matter. MoonLake's shares rose 19 per cent in extended trading. Merck submitted a nonbinding offer for MoonLake earlier this year, according to the report, which added that the initial approach was rejected but talks could be revived. Merck's approach for MoonLake ahead of late-stage clinical data for its flagship drug puts the biotech on a strong footing to get sold, the report said. There was no guarantee a deal would happen and there was a possibility that other buyers would emerge, the FT reported. Merck and MoonLake did not immediately respond to Reuters requests for comment. Merck has relied on its best-seller Keytruda to fuel its growth for years, but the drug's patents will begin to expire in 2028. It has also been seeing declining revenue in China from its Gardasil vaccine. REUTERS
